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Abstract Diacerein is a symptomatic slow-acting drug
in osteoarthritis (SYSADOA) with anti-inflammatory,
anti-catabolic and pro-anabolic properties on cartilage and
synovial membrane. It has also recently been shown to
have protective effects against subchondral bone
remodelling. Following the end of the revision procedure
by the Pharmacovigilance Risk Assessment Committee of
the European Medicines Agency, the European Society
for Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis (ESCEO) constituted a panel of 11 experts
to better define the real place of diacerein in the
armamentarium for treating OA. Based on a literature
review of clinical trials and meta-analyses, the ESCEO
confirms that the efficacy of diacerein is similar to that of
non-steroidal anti-inflammatory drugs (NSAIDs) after the
first month of treatment, and superior to that of
paracetamol. Additionally, diacerein has shown a pro-
longed effect on symptoms of several months once
treatment was stopped. The use of diacerein is associated
with common gastrointestinal disorders such as soft stools
and diarrhoea, common mild skin reactions, and,
uncommonly, hepatobiliary disorders. However, NSAIDs
and paracetamol are known to cause potentially severe
hepatic, gastrointestinal, renal, cutaneous and cardiovas-
cular reactions. Therefore, the ESCEO concludes that the
benefit–risk balance of diacerein remains positive in the
symptomatic treatment of hip and knee osteoarthritis.
Furthermore, similarly to other SYSADOAs, the ESCEO
positions diacerein as a first-line pharmacological
background treatment of osteoarthritis, particularly for
patients in whom NSAIDs or paracetamol are
contraindicated.
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Key Points
Randomised clinical trials show that diacerein has a
similar efficacy compared with NSAIDs on
osteoarthritis symptoms.
Diacerein has an acceptable safety profile,
particularly in comparison with that of NSAIDs and
paracetamol.
The ESCEO positions diacerein as a first-line
pharmacological background treatment of
osteoarthritis.
1 Introduction
Osteoarthritis (OA) is the most frequent form of arthritis,
and one of the leading causes of disability among older
adults worldwide [1]. For individuals, the burden of OA
also includes persistent background pain (aching) and
intermittent but generally more intense pain. Together with
disability, pain contributes to a significant reduction in
quality of life.
The management of OA includes pharmacological
therapies, which are mostly symptomatic [2]. Paracetamol
is the first-line oral analgesic, whilst oral non-steroidal anti-
inflammatory drugs (NSAIDs), including selective
cyclooxygenase-2 (COX-2) inhibitors, are the mainstay of
therapy [3, 4]. These drugs are considered as rapid-acting
drugs in OA and are recommended by rheumatology
societies [2, 5, 6] and government agencies [7].
Symptomatic slow-acting drugs for OA (SYSADOAs)
such as glucosamine, chondroitin sulphate and diacerein
are used for non-acute treatment. Although there is rela-
tive general agreement on many OA management
recommendations across organisations, there is still no
consensus on the place of SYSADOAs. In general, they
are considered supplementary to analgesics and NSAIDs,
whereas the European Society for Clinical and Economic
Aspects of Osteoporosis and Osteoarthritis (ESCEO)
places SYSADOAs as pharmacological background
treatment; that is, first chronic therapy that may improve
or control symptoms [8].
Diacerein is an anthraquinone derivative, of which the
active metabolite is rhein. Its positioning in the algorithm
established by the ESCEO [8] had not been formalised
because, at the time of publication, diacerein was under
review by the Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicines Agency
(EMA). Following the assessment of the PRAC, the
ESCEO felt the need to evaluate the role of diacerein in
clinical practice and constituted a panel of experts to define
its place in the management of OA. This article expresses
the reasoned conclusions drawn by the ESCEO working
group on diacerein.
2 ESCEO Working Group Process
The ESCEO invited 11 experts in musculoskeletal diseases
(rheumatologists, clinical epidemiologists and scientists) to
be part of the working group. Four members had already
been involved in clinical or preclinical research on
diacerein, two of them being current diacerein prescribers;
all were proficient in analysing and interpreting clinical
trial evidence related to OA.
Five of the participants were entrusted with the task of
preparing a review on the mode of action, efficacy and
safety of diacerein in the treatment of OA. A literature
search was conducted in May 2015 using the MEDLINE/
PubMed database. The search strategy included a combi-
nation of the following terms: ‘diacerein’, ‘diacetylrhein’,
‘diacerhein’, ‘rhein’ and ‘osteoarthritis’. Filter settings
were ‘English’, ‘French’, ‘German’, ‘Spanish’ or ‘Italian’
languages. This literature search yielded 179 hits, of which
108 (57 original research papers, 51 reviews, meta-analyses
or opinion-based articles) were retrieved according to their
relevance to the topics mentioned above: 42 were related to
the mode of action of diacerein, 60 dealt with its clinical
efficacy, and 45 contained information on the safety of
diacerein. Additional references were selected from the
reference lists of the retrieved articles to broaden the
literature search.
The outcome of this review was finally discussed by the
11 experts at a one-day meeting in June 2015.
3 The Mechanism of Action of Diacerein
in Osteoarthritis
3.1 In Vitro Studies
The principal mechanism of action of diacerein is to inhibit
the interleukin-1b (IL-1b) system and related downstream
signalling [9]. Diacerein has been shown to impact the
activation of IL-1b via a reduced production of IL-1 con-
verting enzyme [10], as well as to affect the sensitivity to
IL-1 by decreasing IL-1 receptor levels on the cell surface
of chondrocytes [11] and by indirectly increasing IL-1
receptor antagonist production [12, 13]. Production of
IL-1b may also be affected, as diacerein has been shown to
inhibit the IL-1b-induced activation of transcription factor
NF-jB, which stimulates pro-inflammatory cytokine
expression [14–16]. Downregulation of IL-1 levels has
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been confirmed in the synovial fluid of patients with knee
OA [17].
Besides its anti-inflammatory properties, diacerein has
been shown to have anti-catabolic [15, 16] and pro-ana-
bolic [15, 18–20] effects on cartilage and synovial mem-
brane, as well as protective effects against subchondral
bone remodelling (Table 1) [21].
3.2 Animal Models of Osteoarthritis
Beneficial effects of diacerein on cartilage and sub-
chondral bone have been observed in various animal
models of OA. Diacerein consistently reduced cartilage
loss compared with untreated controls [26–30], improved
cartilage lesions in the experimental hip chondrolysis
model of immature Beagle dogs [31], and induced an
increase in bone mineral density as well as a decrease in
the thickness of the subchondral bone plate [28]. Finally,
prophylactic treatment with diacerein has been shown to
delay arthritis secondary to meniscectomy in a rat model
of OA [32].
4 Clinical Data on the Efficacy of Diacerein
4.1 Effects on Pain and Physical Function
Efficacy of diacerein was evaluated in 16 published
clinical trials [33–48]. Patients included in these studies
were representative of patients in a real-life setting, so
that the outcomes can be extrapolated to the general
population.
Four published meta-analyses assessed the symptomatic
effects of 100 mg/day diacerein [49–52]. Each of them
included a different set of clinical studies (Table 2).
In a meta-analysis of 19 published and unpublished
studies including a total of 2637 patients, Rintelen and co-
authors [49] showed a statistically significant superiority of
diacerein over placebo at the end of treatment with respect
to pain reduction and physical function improvement. At
the end of the treatment-free follow-up period, diacerein
was also found to be significantly better than placebo on
pain (no pooled data on function), thus demonstrating a
carry-over effect after stopping treatment. When compared
with standard treatments (mostly NSAIDs), no statistically
significant difference regarding pain and physical function
was observed at the end of the treatment period. However,
at the end of the treatment-free follow-up period, pooled
Glass’ standardised mean differences on pain and joint
function showed that diacerein was significantly superior
over the active comparator (Fig. 1).
Using the strict Cochrane criteria for meta-analyses,
Fidelix and co-authors reviewed seven published ran-
domised controlled trials in a total of 2069 patients with
OA [50]. Three more clinical trials [44, 45, 47] were
included in the updated Cochrane Review [51] compared
with the 2006 version. The main differences in outcomes
between the two meta-analyses are shown in Table 3.
Thus, in the Cochrane 2014 version, the mean-weighted
differences (MWD) tended to increase in favour of diac-
erein compared with placebo. The authors concluded that
diacerein had a small but significant effect on overall pain
after 3–36 months of treatment. In addition, results of a
subgroup analysis demonstrating a carry-over effect of
diacerein compared with placebo or NSAIDs on pain and
physical function were presented.
Finally, another meta-analysis on randomised, placebo-
controlled trials with diacerein was published by Bartels
et al. [52]. The authors included six studies with a total of
1533 patients. The effect size (ES) was estimated using
Table 1 Summary of the
effects of diacerein/rhein on
articular tissues
Cartilage/synovial membrane
Anti-catabolic ; IL-1b-induced MMP-1, MMP-3, MMP-13, ADAMTS-4, ADAMTS-5 [15, 22]
; IL-1b-induced iNOS, NO [13, 16, 19, 23]
: IL-1b-induced PGE2, COX-2 [21]
Pro-anabolic : collagen, proteoglycans, hyaluronan [15, 19, 20]
Subchondral bone
Osteoblasts : PGE2, COX-2 [21]
; vitamin D3-induced osteocalcin ? ; uPA [21]
; DKK-1, DKK-2 [24]
Osteoclasts ; MMP-13, cathepsin K [25]
; osteoclast survival, pre-osteoclast differentiation [25]
Adapted with permission from Martel-Pelletier and Pelletier [9]
ADAMTS disintegrin and metalloproteinase domain with thrombospondin motifs, COX-2 cyclooxygenase-
2, DKK Dickkopf, IL-1b interleukin-1b, antagonist, iNOS inducible nitric oxide synthase, MMP metallo-
proteinase, NO nitric oxide, PGE2 prostaglandin E2, uPA urokinase-type plasminogen activator
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Hedges’ standardised mean difference. For pain reduction,
results showed that the combined ES was -0.24 (95 % CI
-0.39 to -0.08, p = 0.003, I2 = 56 %), favouring diac-
erein. There was also a statistically significant improve-
ment in physical function (p = 0.01, I2 = 11 %).
4.2 Structure-Modifying Effects
Two clinical studies assessed the impact of diacerein on
radiological signs of OA: one was conducted in patients
with hip OA [40], the other in patients with knee OA [41].
The ECHODIAH (Evaluation of the Structure-Modify-
ing Effects of Diacerein in Hip Osteoarthritis) study [40]
was a 3-year, multicentre, randomised, double-blind, pla-
cebo-controlled trial evaluating the potential structure-
modifying effects of diacerein in 507 patients with painful
and structurally advanced primary hip OA. Sixty-one
patients did not have any pelvic X-ray after the start of
treatment and were therefore excluded from the analysis.
The between-group comparison in the number of
patients with a joint space narrowing (JSN) of at least
0.5 mm showed a statistically significant difference in
Table 2 Clinical studies included in the meta-analyses evaluating diacerein
Study Blinding Duration Control Rintelen et al.
(2006) [49]




Fidelix et al. [51]
(Cochrane 2014)
Fagnani et al. (1998) [36] Open 6 months Standard ?
Chantre et al. (2000) [38] DB 4 months DC ? ? ?
Mattara (1985) [53] DB 3 months NSAID ?
Pietrogrande et al. (1985)
[54]
DB 1 month NSAID ?
Fioravanti and Marcolongo
(1985) [55]
DB 2 months NSAID ?
Mordini et al. (1986) [56] DB 2 months NSAID ?
Mantia (1987) [57] DB 3 months NSAID ?
Portioli (1987) [58] DB 3 months NSAID ?
Marcolongo et al. (1988)
[33]
DB 2 months NSAID ?
Tang et al. (2004) [59]/
Zheng et al. (2006) [43]
DB 3 months NSAID ? ? ?
Louthrenoo et al. (2007)
[45]
DB 4 months NSAID ? ?
Pham et al. (2004) [41] DB 12 months NSAID/
i.a. HA
? ? ? ?
Nguyen et al. (1994) [34] DB 2 months Placebo/
NSAID
? ? ? ?
Ascherl (1995) [60] DB 6 months Placebo ?
Schulitz (1994) [61] DB 3 months Placebo ?
Lequesne et al. (1998) [37] DB 6 months Placebo ? ? ? ?
Pelletier et al. (2000) [39] DB 4 months Placebo ? ? ? ?
Dougados et al. (2001) [40] DB 36 months Placebo ? ? ? ?
Pavelka et al. (2007) [44] DB 3 months Placebo ? ? ?
Brahmachari et al. (2009)
[47]
SB 2 months Placebo ?
DB double-blind, DC Devil’s claw or Harpagophytum procumbens, HA hyaluronic acid, i.a. intra-articular, NSAID non-steroidal anti-inflam-
matory drug, SB single-blind
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favour of diacerein in both the intent-to-treat (ITT) and the
Completer analyses (primary populations of analysis). The
between-group comparison in JSN rate also showed a
statistically significant difference in the Completer analy-
sis, while no difference was observed in the ITT population
using the last-observation-carried-forward imputation
method. Results in the per protocol (PP) population (sec-
ondary analysis) were similar to those in the Completer
data set (Table 4).
The above results in the ECHODIAH study demon-
strated the superiority of diacerein treatment versus pla-
cebo in only three of four co-primary endpoints for JSN
Table 3 Main differences in
results between the Cochrane
Reviews 2006 [50] and 2014
[51]
Fidelix et al. [50]
(Cochrane 2006)
Fidelix et al. [51]
(Cochrane 2014)
Diacerein vs placebo
Pain on VAS (0–100 mm)
N (no. of studies) - I2 1228 (5) - 60 % 1283 (6) - 84 %
WMD (95 % CI) -5.16 (-9.75 to -0.57) -8.65 (-15.62 to -1.68)
WOMAC pain subscale (0–500 mm)
N (no. of studies) - I2 234 (1) - NA 399 (2) - 0 %
WMD (95 % CI) -24.90 (-48.41 to -1.39) -29.33 (-48.45 to -10.20)
WOMAC function subscale (0–1700 mm)
N (no. of studies) - I2 234 (1) - NA 454 (3) - 0 %
WMD (95 % CI) -107.50 (-187.51 to -27.49) -110.92 (-173.88 to -47.97)
Diacerein vs NSAIDs
Pain on walking on VAS (0–100 mm)
N (no. of studies) - I2 184 (1) - NA 213 (1) - NA
WMD (95 % CI) -4.61 (-10.69 to 1.47)a 1.30 (-3.81 to 6.41)
WOMAC pain subscale (0–500 mm)
N (no. of studies) - I2 161 (1) - NA
WMD (95 % CI) 14.00 (-10.15 to 38.15)
WOMAC function subscale (0–1700 mm)
N (no. of studies) - I2 184 (1) - NA 345 (2) - 0 %
WMD (95 % CI) -12.28 (-73.01 to 48.45) 29.50 (-23.17 to 82.17)b
N no. of patients, NA not applicable, I2 heterogeneity index I2, WMD weighted-mean difference, 95 % CI
95 % confidence interval, VAS visual analogue scale,WOMACWestern Ontario and McMaster Universities
Osteoarthritis Index
Mistakes have been observed in the reporting: a values at 4 months of Tang et al. [59] have been included
in the analysis instead of values at 3 months (end of treatment); b baseline values of Tang et al. [59] have
been included in the analysis instead of values at 3 months from Zheng et al. [43]
Fig. 1 Comparison of diacerein
vs placebo (a) and diacerein vs
active comparator (mostly
NSAIDs) (b) regarding pain and
physical function at the end of
the active treatment period, as
well as after the treatment-free
follow-up period (dechallenge)
(Rintelen et al. [49] meta-
analysis). Error bars indicate
95 % confidence intervals.
Glass’ standardised mean
differences greater than 0.8 are
commonly regarded as
clinically relevant
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and failed to demonstrate the structure-modifying effects of
diacerein in patients with hip OA.
The Pham study (2004) [41] was conducted in 301
patients with knee OA. The aim of this 1-year, randomised,
double-blind, placebo-controlled, three-arm trial was to
evaluate the long-term efficacy of three cycles of 3-weekly
intra-articular injections of hyaluronic acid (HA) in the
treatment of symptomatic knee OA compared with oral
diacerein and placebo. A saline solution was used in the
diacerein and placebo groups to maintain the blind.
No statistically significant differences between groups
were observed for JSN. The percentage of patients with a
progression[0.5 mmwas 17.7, 18.9 and 20.3 % (p = 0.90)
in the HA, diacerein and placebo groups, respectively.
5 Clinical Data on the Safety of Diacerein
5.1 Gastrointestinal
Regarding the risk of gastrointestinal disorders, the most
frequently reported events with diacerein were loose stools
and diarrhoea. The laxative effect of diacerein is well
known and results from its anthraquinone chemical
structure.
Bartels et al. [52] calculated that the risk ratio (RR) for
developing diarrhoea under diacerein versus placebo
treatment was 3.51 (95 % CI 2.55–4.83). Fidelix et al. [51]
obtained an RR of 3.52 (95 % CI 2.42–5.11) for diacerein
versus placebo, with an absolute risk increase of 24 %
(95 % CI 12–35). Well in line with these meta-analyses,
Rintelen and co-authors [49] summarised that 39 % of
patients treated with diacerein versus 12 % of patients
receiving placebo experienced at least one episode of loose
stool or diarrhoea.
Diarrhoea was mentioned to be generally mild to
moderate in all publications that make reference to the
severity [35, 40, 44], and occurred in the first 2 weeks of
treatment. No particular pattern of associated disorders
could be detected. In all cases, the diacerein-induced
diarrhoea was reversible after cessation of treatment. Fur-
thermore, diarrhoeal symptoms decreased in most cases
after continuous treatment [62].
The post-marketing surveillance of diacerein showed
that 25 serious cases of diarrhoea were reported. Three of
them concerned elderly patients, who experienced dehy-
dration and electrolyte disorders; one case was fatal and
occurred in a 79-year-old female with a medical history of
arterial hypertension and cardiac arrhythmia [63].
5.2 Cutaneous
The skin was not a target organ for toxicity in short- and
long-term animal toxicology studies. Nevertheless, the
incidence of cutaneous events in the 15 published clinical
trials evaluating diacerein ranged between 1.8 % [35, 36]
and 9.4 % [41]. The present review identified rash, pruritus
and eczema as the most common cutaneous reactions
reported in clinical trials. They are appropriately reflected
in the product information with a frequency of[1/100 and
\1/10).
Furthermore, the available post-marketing data revealed
a few severe cases of cutaneous events: four erythema
multiform, two Stevens-Johnson syndrome (SJS) and three
toxic epidermal necrolysis (TEN) [63].
5.3 Hepatic
Among the 15 published clinical trials evaluating
diacerein, only Zheng et al. [43] reported the occurrence of
a hepatic adverse event: one treatment discontinuation due
to increase in hepatic enzymes. The PRAC performed a
more complete analysis of available data and retrieved
seven clinical trials showing abnormalities of liver tests.
Table 4 Joint space narrowing
measured on pelvic X-ray at
3 years: intent-to-treat,
Completer and per protocol data
sets (ECHODIAH study by
Dougados et al. [40])
Parameter Diacerein Placebo p value
ITT data set, N 221 225
C0.5 mm JSN, N (95 % CI) 51 % (44–57) 60 % (54–67) 0.036*
JSN rate (mm/year), mean (SD) 0.39 (0.75) 0.39 (0.81) ns**
Completer data set, N 131 138
C0.5 mm JSN, N (95 % CI) 47 % (39–56) 62 % (54–70) 0.007*
JSN rate (mm/year), mean (SD) 0.18 (0.25) 0.23 (0.23) 0.042**
PP data set, N 101 114
C0.5 mm JSN, N (95 % CI) 49 % (38–59) 68 % (58–76) 0.003*
JSN rate (mm/year), mean (SD) 0.18 (0.22) 0.25 (0.23) 0.011**
ITT intent-to-treat, PP per protocol, JSN joint space narrowing, N number of patients, 95 % CI 95 %
confidence interval, SD standard deviation, ns non-significant
* Log rank test, ** Mann–Whitney test
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These were mostly characterised by mild/moderate liver
enzyme increase (ALT, AST\5 ULN) without increases
in bilirubin [63].
A total of 89 cases within the post-marketing surveil-
lance were considered as hepatic reactions. The most fre-
quent reactions were liver function test abnormalities (41
cases) [63]. One case of hepatic failure had a fatal outcome
and a close temporal association with diacerein [64].
The extensive preclinical animal toxicology data with
diacerein indicated that the liver was not a target organ for
toxicity. The mechanism of action of this hepatic toxicity is
not fully understood, but an idiosyncratic mechanism is
suggested.
5.4 Cardiovascular
Diacerein does not appear to show cardiovascular toxicity.
Indeed, a toxicology study designed in accordance with
ICH S7A guidelines demonstrated that diacerein at 5 and
30 mg/kg/day for 7 consecutive days, and at 60 and
200 mg/kg/day for 4 and 3 consecutive days, respectively,
did not affect the cardiovascular system in the conscious
dog [65]. The doses used in this study were between 3.6
times and about 143 times the recommended dose in
humans (1.4 mg/kg/day based on a 70 kg person).
More significantly, no signal from post-marketing
surveillance for acute coronary syndromes or myocardial
infarctions was reported in more than 20 years of
experience with diacerein.
6 Discussion
The overall analysis of randomised controlled clinical
studies and meta-analyses confirmed the efficacy of diac-
erein in the symptomatic treatment of knee and hip OA. An
ES on pain of 0.24 (95 % CI 0.08–0.39) has been reported
[52], a value considered to be low but clinically relevant in
OA [66]. Furthermore, as the ES of diacerein and other
anti-OA agents is based on the difference between the
placebo and the active drug effects, it is relevant to note
that unequivocal evidence for a large placebo response has
been demonstrated in randomised clinical trials of OA
(ES = 0.51, 95 % CI 0.46–0.55) [67]. The ES of diacerein
should therefore be assessed bearing in mind this large
placebo response.
Although NSAIDs have shown a more rapid onset of
action than diacerein, efficacy of these drugs on pain and
joint function was comparable after the first month of
treatment. On the other hand, unlike NSAIDs, diacerein has
shown a prolonged effect of several months once treatment
was stopped. Evidence published by the Osteoarthritis
Research Society International (OARSI) indicated that
diacerein had a greater efficacy on pain reduction in OA
than paracetamol (ES = 0.14, 95 % CI 0.05–0.22), and a
similar efficacy compared with NSAIDs (ES = 0.29, 95 %
CI 0.22–0.35) [6].
The use of diacerein is associated with common gas-
trointestinal disorders (mostly soft stools and diarrhoea),
common mild skin reactions, and uncommon hepatobiliary
disorders. Frequent cases of severe diarrhoea and rare cases
of potentially serious hepatotoxicity were reported; a risk
of cutaneous drug reactions could not be excluded [63].
In order to minimise this risk, it is recommended to start
diacerein treatment with half the recommended dose
(50 mg/day) for the first 2–4 weeks, the laxative properties
of diacerein being dose-dependent [39]. In the same con-
text, starting a treatment with diacerein is not recom-
mended in patients older than 65 years who are considered
to be more vulnerable to diarrhoeal complications [68]. In
parallel, laxatives should be avoided, and concomitant
treatment with medicines that can lead to hypokalaemia
should be especially monitored. Finally, it is common
sense to stop treatment as soon as diarrhoea occurs. To
prevent the risk of hepatotoxicity, diacerein is contraindi-
cated in patients with current or a history of liver disease
and, therefore, patients should be screened for major causes
of active hepatic disease before starting the treatment.
Caution should be exercised when diacerein is used con-
comitantly with products associated with hepatic injury.
Treatment should be stopped if elevation of hepatic
enzymes or suspected signs or symptoms of liver damage
are detected.
Safety of diacerein should be put in the context of
paracetamol and NSAID use, drugs that have been shown
to cause potentially severe hepatic [69–71], gastrointestinal
[72, 73], renal [74–77], cutaneous [78] and cardiovascular
reactions [79–82]. For example, an incidence of clinically
apparent liver injuries of 10.0 per 100,000 patient-years of
treatment with NSAIDs has been reported [83], and
paracetamol is responsible for the higher rate of hospital-
isations for hepatic failures [69]. In comparison, the risk of
hepatic disorders with diacerein (including elevated hepatic
enzymes) was 1.68 per 100,000 patient-years of treatment.
Regarding cutaneous reactions, NSAIDs have been repor-
ted to be the second most common cause of drug-induced
hypersensitivity reaction [84], and among the drugs that are
the most frequently associated with SJS and TEN [85].
NSAIDs are also known for increasing the risk of cardio-
vascular events, including congestive heart failure and
infarction/stroke [73, 86, 87].
Several rheumatology societies, such as the European
League Against Rheumatism (EULAR) [2] and the OARSI
[5, 6], have included diacerein in their therapeutic guide-
lines as a treatment option in OA. However, a review
evaluating the benefit–risk ratio of diacerein conducted by
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the PRAC was initiated in November 2012 following the
request of the French Medicines Agency. One year later,
the PRAC/EMA initially recommended the suspension of
the marketing authorisations for diacerein, but following
re-examination, additional proposals to manage the risks of
diacerein were considered. As a result, in July 2014, the
PRAC/EMA confirmed the safety profile of diacerein,
which has not changed in 20 years, and concluded that its
benefit–risk balance remained positive in the symptomatic
treatment of hip and knee OA [63].
Based on the opinion of 11 experts in rheumatology, the
ESCEO working group underlines the PRAC/EMA con-
clusions that the benefits of diacerein outweigh its risks and
confirms that diacerein is an interesting option in the
physician’s armamentarium for treating OA. These con-
clusions are also in line with those of a review recently
published by two independent Australian experts [88].
Therefore, similarly to other SYSADOAs, the ESCEO
positions diacerein as a first-line background pharmaco-
logical treatment of OA. However, it should be avoided in
patients with a known propensity for diarrhoea, but would
be particularly beneficial in patients with contraindications
to NSAIDs or paracetamol.
Diacerein is a compound with a long history but whose
effects are still not fully understood. Besides the evidence
of its efficacy in knee and hip OA, there are very few data
on its effect in other OA locations such as the hand, as well
as on different types of patient profiles [89], or OA sub-
types. Further research also needs to be performed to define
the real potential of diacerein on disease progression with
well designed, high quality, structure-modifying clinical
trials. Then, depending on the outcomes on cartilage and
knowing the proven carry-over therapeutic effect of
diacerein, one might question whether continuous or
intermittent treatment would be the most reasonable.
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